These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 24739665)

  • 21. Imatinib for hepatocellular cancer--focus on pharmacokinetic/pharmacodynamic modelling and liver function.
    Treiber G; Wex T; Schleyer E; Troeger U; Hosius C; Malfertheiner P
    Cancer Lett; 2008 Feb; 260(1-2):146-54. PubMed ID: 18083304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays.
    Rezende VM; Rivellis A; Novaes MM; de Alencar Fisher Chamone D; Bendit I
    Drug Des Devel Ther; 2013; 7():699-710. PubMed ID: 23946646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring of imatinib targeted delivery in human leukocytes.
    Kralj E; Žakelj S; Trontelj J; Pajič T; Preložnik Zupan I; Černelč P; Ostanek B; Marc J; Kristl A
    Eur J Pharm Sci; 2013 Sep; 50(1):123-9. PubMed ID: 23643738
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A.
    Blake SJ; Hughes TP; Lyons AB
    Exp Hematol; 2012 Aug; 40(8):612-21.e6. PubMed ID: 22521768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Efficacies of hematopoietic stem cell transplantation plus imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparative study].
    Chen J; Wu DP; Chen F; Zhao Y; Sun AN; Qiu HY
    Zhonghua Yi Xue Za Zhi; 2013 Feb; 93(8):583-7. PubMed ID: 23663336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Possible role of the intestinal P-450 enzyme system in a cyclosporine-clarithromycin interaction.
    Sketris IS; Wright MR; West ML
    Pharmacotherapy; 1996; 16(2):301-5. PubMed ID: 8820476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
    Peng B; Hayes M; Resta D; Racine-Poon A; Druker BJ; Talpaz M; Sawyers CL; Rosamilia M; Ford J; Lloyd P; Capdeville R
    J Clin Oncol; 2004 Mar; 22(5):935-42. PubMed ID: 14990650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat.
    Lin G; Wang C; Qiu X; Wang Z; Han A; Xu T; Kan X; Hu G
    Drug Dev Ind Pharm; 2014 Dec; 40(12):1616-22. PubMed ID: 24053419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus.
    Garg V; van Heeswijk R; Lee JE; Alves K; Nadkarni P; Luo X
    Hepatology; 2011 Jul; 54(1):20-7. PubMed ID: 21618566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects.
    Dutreix C; Peng B; Mehring G; Hayes M; Capdeville R; Pokorny R; Seiberling M
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):290-4. PubMed ID: 15138710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
    Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects.
    Kim KA; Park SJ; Kim C; Park JY
    Clin Ther; 2013 Oct; 35(10):1595-602. PubMed ID: 24060561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
    Teng JF; Mabasa VH; Ensom MH
    Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients.
    Oellerich M; Armstrong VW; Streit F; Weber L; Tönshoff B
    Clin Biochem; 2004 Jun; 37(6):424-8. PubMed ID: 15183289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia.
    Racil Z; Razga F; Klamova H; Voglova J; Belohlavkova P; Malaskova L; Potesil D; Muzik J; Zackova D; Polakova KM; Zdrahal Z; Malakova J; Suttnar J; Dyr J; Mayer J
    Hematol Oncol; 2014 Jun; 32(2):87-93. PubMed ID: 23963760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP3A5 polymorphism effect on cyclosporine pharmacokinetics in living donor renal transplant recipients: analysis by population pharmacokinetics.
    Song J; Kim MG; Choi B; Han NY; Yun HY; Yoon JH; Oh JM
    Ann Pharmacother; 2012 Sep; 46(9):1141-51. PubMed ID: 22947591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
    Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
    Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolism and disposition of imatinib mesylate in healthy volunteers.
    Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
    Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.